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Abstract
Background: vitamin D deficiency has been associated with an increased risk of mortality, but whether this relationship is
causal or linked to co-existent comorbidity and adverse life factors remains uncertain. Our objective was to determine whether
endogenous 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone (PTH)
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levels predicted all-cause, cardiovascular and cancer mortality independently of health and lifestyle factors.
Setting: prospective cohort analysis within the European Male Ageing Study.
Participants: 2,816 community-dwelling men aged 40–79 years at baseline.
Methods: Cox regression was used to examine the association of all-cause mortality with 25(OH)D, 1,25(OH)2D and PTH; car-
diovascular and cancer mortality were modelled using competing-risks regression. Results were expressed as hazard ratios (HR) and
95% confidence intervals (CIs) for Cox models; sub-
hazard ratios (SHR) and 95% CIs for competing-risks models.
Results: a total of 187 men died during a median of 4.3 years of follow-up. Serum levels of 25(OH)D (per 1 SD decrease:
HR= 1.45; 95% CI = 1.16, 1.81) and 1,25(OH)2D (per 1 SD decrease: HR= 1.20; 95% CI = 1.00, 1.44) were associated with an
increased risk of all-cause mortality after adjusting for age, centre, smoking, self-reported morbidities, physical activity and functional
performance. Only levels of 25(OH)D <25 nmol/l predicted cancer mortality (SHR= 3.33; 95% CI = 1.38, 8.04).
Conclusion: lower 25(OH)D and 1,25(OH)2D levels independently predicted all-cause mortality in middle-aged and older
European men. Associations with cancer mortality were only observed among men with very low levels of 25(OH)D. These asso-
ciations were only partially explained by the range of adverse health and lifestyle factors measured here.
Keywords: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, parathyroid hormone, mortality, population based, older people
Introduction
Vitamin D inadequacy has been reported to be widespread
among older people [1, 2]. Serum levels of 25-hydroxyvitamin
D (25(OH)D) are used to establish an individual’s vitamin D
status, while the biologically active molecule, 1,25-dihydroxyvi-
tamin D (1,25(OH)2D), is produced by the hydroxylation of
25(OH)D primarily in the kidneys under the regulation of
parathyroid hormone (PTH) and serum calcium [3]. Although
the essential role played by the vitamin D endocrine axis in
skeletal homeostasis is well recognised, low serum levels of 25
(OH)D and elevated levels of PTH have also been linked to
other health outcomes, including cognitive decline [4], cardio-
vascular diseases [5], depression [6], type 2 diabetes [7] and
cancer [8].
With respect to vitamin D deficiency and mortality risk,
recent systematic reviews of randomised controlled trials
(RCTs) examining the potential value of vitamin D supple-
mentation have highlighted contradictory findings. A meta-
analysis of RCTs carried out by Autier and Gandini found
vitamin D supplementation reduced all-cause mortality by 7%
[9]. However, Bjelakovi et al. [10] observed that vitamin D3
supplementation decreased mortality in elderly women, while
Rejnmark et al. [11] found consistently reduced mortality only
in elderly subjects randomised to receive vitamin D supple-
ments in combination with calcium. Similar inconsistencies
have also been seen among prospective observational studies
describing associations between low 25(OH)D and all-cause
[12, 13], cancer [14, 15] and cardiovascular mortality [16].
Fewer prospective studies have examined the effects of 1,25
(OH)2D and PTH. Associations have been observed between
low 1,25(OH)2D levels and all-cause and cardiovascular
mortality among coronary angiography patients [17], high
PTH levels and mortality among frail older people [18], and
elevated PTH within the normal range and cardiovascular
mortality in community-based older men [19].
While epidemiological evidence suggests a possible link
between optimal vitamin D status and decreased mortality
[13], there are few data describing the association of the key
metabolites of the vitamin D axis with mortality among
community-dwelling, middle-aged and older men. An unre-
solved question is whether vitamin D deficiency and optimal
functioning of the vitamin D endocrine axis is an important,
and potentially underestimated, cause of premature death.
We utilised data from the European Male Ageing Study
(EMAS) to examine whether 25(OH)D, 1,25(OH)2D and
PTH predicted all-cause, cardiovascular and cancer mortality
independently of health and lifestyle factors.
Methods
Participants and study design
The design and recruitment for the EMAS have been described
previously [20]. Briefly, an age-stratified sample of 3,369 men
aged 40–79 (mean ± SD: 60 ± 11) years were recruited from
population registers in eight European centres (Florence, Italy;
Leuven, Belgium; Malmö, Sweden; Manchester, UK; Santiago
de Compostela, Spain; Łódź, Poland; Szeged, Hungary; Tartu,
Estonia). Participants completed a postal questionnaire (PQ)
and attended a research clinic for further assessments. The
men were invited to attend a follow-up assessment and com-
pleted another PQ a median of 4.3 years later (range 3.0–5.7
years). Ethical approval was obtained in accordance with each
centre’s institutional requirements, with all participants provid-
ing written informed consent.
Assessments
The PQ included questions concerning general health and
lifestyle, including smoking and alcohol consumption.
Participants were asked whether they were currently being
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treated for various morbidities including heart conditions,
hypertension, bronchitis, asthma, diabetes, liver disease, kidney
conditions, prostate disease and thyroid disorders, and if they
had ever been treated for cancer or suffered a stroke.
The assisted questionnaire included the Physical Activity
Scale for the Elderly (PASE) [21], a self-report instrument to
measure levels of physical activity among older individuals.
Physical function was assessed during the clinic visit using
Reuben’s Physical Performance Test (PPT) [22], an objective
measure of functional performance. Anthropometric mea-
surements included height, weight and waist circumference.
Biochemistry
A fasting blood sample was obtained from all subjects.
Processed serum was stored at −80°C and shipped frozen to
central laboratories for measurement of 25(OH)D and 1,25
(OH)2D3 (Katholieke Universiteit Leuven, Belgium) and
PTH (University of Santiago de Compostela, Spain). 25(OH)
D levels were determined using radioimmunoassay (RIA kit,
DiaSorin, Stillwater, MN, USA). Intra- and inter-assay coeffi-
cients of variation (CVs) for 25(OH)D were 11 and 8%, re-
spectively. The detection limit was 4.0 nmol/l. 1,25(OH)2D3
was measured by liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) as a lithium adduct according to
Casetta et al. [23] using a Shimadzu Prominence HPLC
(Shimadzu, Kyoto, Japan) coupled to an AB Sciex API 5500
QTRAP tandem mass spectrometer (Sciex, Warrington,
UK). Modifications to the original methodology have been
described previously [24]. The limit of quantification for 1,25
(OH)2D3 was <15.6 pmol/l, with interday CVs for pooled
serum of 6% for serum with a mean concentration of 140
pmol/l and 10% for serum with a mean concentration of 18
pmol/l. PTH was assayed using a chemiluminescence im-
munoassay (Nichols Advantage Bio-Intact PTH, Quest
Diagnostics, Madison, NJ, USA), with manufacturer’s intra-
and inter-assay CVs of 6 and 3%, respectively, and a detec-
tion limit of 0.2 pmol/l. Serum creatinine concentration
(measure of renal function) was assayed in each centre using
the Jaffe method [25]. Creatinine intra- and inter-assay CVs
ranged from 0.7 to 1.9% and 1.6 to 3.5%, respectively, with
detection limits between 5.3 and 18.0 μmol/l.
Mortality
Deaths that occurred during the follow-up period were deter-
mined from contact by relatives on receipt of the PQ or, if
this was not returned, by further enquiries to ascertain the
participant’s vital status. The enquiry procedure varied
between centres and included review of medical records/
death registers and telephone follow-up. Deaths were verified
from death certificates (28%), death registers (37%) and
medical/hospital records (24%). Eleven percent of deaths
were unverified and information from the family member/
contact person was the only source. Deaths were categorised
where possible as being due to cardiovascular diseases,
cancer or other causes, preferentially using the same source
as that used to verify the death. Men who did not reply to the
follow-up PQ and for whom no further information was
available were classified as ‘lost to follow-up’.
Statistical analysis
Analyses were conducted using STATA SE v11.2 (StataCorp,
College Station, TX, USA). Smoking was categorised as
current, former or never; alcohol consumption as never,
intake on ≤2 days/week or ≥3 days/week; and self-reported
morbidities as none, 1 or ≥2. Participants contributed
follow-up time from the date of admission in the baseline
survey to the date of follow-up assessment or date of death.
Deaths occurring up to 31 December 2008 were included in
this analysis.
We used t-tests or Wilcoxon rank-sum tests to assess
associations between vital status and continuous variables
and the χ2-test for associations with categorical variables.
Associations of 25(OH)D, 1,25(OH)2D3 and PTH with
health and lifestyle factors that could potentially confound
associations with mortality were assessed using linear regres-
sions adjusted for baseline age, with results reported as beta-
coefficients (β) and 95% CIs.
Cox proportional hazard models were used to assess the as-
sociation between all-cause mortality and 25(OH)D, 1,25
(OH)2D3 or PTH, with results reported as hazard ratios (HR)
and 95% CI. To aid interpretation of HRs the values for 25
(OH)D, 1,25(OH)2D3 and PTH as continuous variables were
standardised as z scores. This provided a comparative measure
of the magnitude of the association between each hormone
(per SD change) and all-cause mortality, independent of the
units of concentration. 25(OH)D, 1,25(OH)2D3 and PTH
were categorised into quartiles prior to analysis, with the refer-
ence category for 25(OH)D and 1,25(OH)2D3 being the
highest quartile and for PTH the lowest quartile. Data were
also analysed after categorising 25(OH)D levels as: ≥75 nmol/
l (reference; n= 828); 50.0–74.9 nmol/l (n= 873); 25.0–49.9
nmol/l (n= 904); and <25.0 nmol/l (n= 211). Although no
current consensus on optimal levels of vitamin D exist, a
recent report on dietary requirements for calcium and vitamin
D from the Institute of Medicine (IOM) concluded that a
serum 25(OH)D concentration of 50 nmol/l would cover the
requirements of at least 97.5% of the population [26]. All Cox
regressions were initially performed unadjusted, then with ad-
justment for baseline age and centre. To obtain parsimonious
final models, additional adjustments were restricted to those
health and lifestyle factors associated with both all-cause mor-
tality and 25(OH)D, 1,25(OH)2D3 or PTH. Model goodness
of fit was assessed using Nelson–Aalen cumulative hazard
plots, and the proportional-hazards assumption tested on the
basis of Schoenfeld residuals after fitting each model [27].
Associations between cause-specific mortality (cardiovas-
cular or cancer) and 25(OH)D, 1,25(OH)2D3 or PTH, were
modelled using competing-risks regression with results
expressed as sub-hazard ratios (SHR) and 95% CIs.
Competing-risks regression generalises survival analysis to
situations where subjects are exposed to more than one
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cause of failure, e.g. cancer mortality versus non-cancer mor-
tality, allowing more robust estimation of cause-specific
hazards [28]. Competing-risks regressions were adjusted for
the same factors as in the Cox models. To minimise potential
bias by reverse causality, analyses on cardiovascular mortality
were repeated excluding subjects who self-reported at base-
line ‘heart conditions’ and/or ‘ever suffered a stroke’, and
analyses on cancer mortality were repeated excluding subjects
who self-reported ‘ever been treated for cancer’.
Results
From the 3,369 baseline participants, 440 men were lost to
follow-up and 113 had missing serum vitamin D metabolite
data. Among the remaining 2,816 men, there were 187
deaths during a median 4.3 years follow-up, an overall mor-
tality of 6.6%. The characteristics of the analysis sample by
vital status are shown in Table 1. Compared with survivors,
those who died were older, had significantly lower levels of
25(OH)D and 1,25(OH)2D3 and higher levels of PTH and
creatinine. The men who died also differed significantly from
survivors in terms of their baseline physical activity (PASE),
physical function (PPT), smoking status, alcohol consump-
tion and morbidity burden. The associations of 25(OH)D,
1,25(OH)2D3 and PTH with a range of health and lifestyle
factors in age adjusted linear regressions are summarised in
the Supplementary data available in Age and Ageing online,
Appendix 1.
Table 2 summarises the results from the Cox regression
models with 25(OH)D, 1,25(OH)2D3 and PTH predicting
all-cause mortality. Models were adjusted for age and centre
[Model 1], and additionally for smoking, alcohol consumption,
morbidities, PASE score, PPT rating and creatinine[Model 2].
Unadjusted Cox regressions showed HRs of 1.88 (95%
CI = 1.55, 2.26) per SD decrease in 25(OH)D, 1.40 (95%
CI = 1.19, 1.65) per SD decrease in 1,25(OH)2D3 and 1.28
(95% CI = 1.14, 1.43) per SD increase in PTH. Serial adjust-
ment for age, centre and other confounders attenuated this
relationship, such that the respective HRs were 1.45 (95%
CI = 1.16, 1.81) per SD decrease in 25(OH)D, 1.24 (95%
CI = 1.02, 1.51) per SD decrease in 1,25(OH)2D3 and 1.04
(95% CI = 0.90, 1.20) per SD increase in PTH. The associ-
ation between lower 25(OH)D and increased mortality was
also observed when 25(OH)D levels were classified into
quartiles or categories. In fully adjusted models[Model 2], men
who were in the lowest quartile of 25(OH)D (<40 nmol/l)
had an HR of 2.37 (95% CI = 1.33, 4.24) compared with
those in the highest quartile (>79.1 nmol/l), while those
with 25(OH)D <25 nmol/l at baseline had an HR of 2.28
(95% CI = 0.20, 4.34) compared with those with a 25(OH)D
level of ≥75 nmol/l. Similar associations were observed
when 1,25(OH)2D3 was classified into quartiles, with men in
the lowest quartile (<114 pmol/l) having an HR for mortal-
ity of 1.77 (95% CI = 1.05, 2.96) compared with those in the
highest quartile (>164 pmol/l). The relationship between
PTH quartiles and mortality was less clear, however, with
only men in the third quartile of PTH (2.77–3.60 pmol/l)
having a significantly reduced risk of mortality (HR = 0.56;
95% CI = 0.33, 0.95) compared with those in the lowest
quartile (<2.15 pmol/l).
Results from the fully adjusted competing-risks regres-
sions are summarised in Table 3. There was no association
between 25(OH)D (per SD decrease) and cardiovascular
mortality (SHR = 1.38; 95% CI = 0.95, 1.99; P= 0.09), nor
any evidence that 25(OH)D levels (either quartiles or categor-
ies) were associated with cardiovascular mortality. The associ-
ation between 25(OH)D (per SD decrease) and cancer
mortality also failed to reach significance (SHR = 1.31; 95%
CI = 0.92, 1.86; P= 0.14), although when 25(OH)D was clas-
sified into categories those men with a 25(OH)D level of
<25 nmol/l at baseline had a significant SHR for cancer mor-
tality of 3.33 (95% CI = 1.38, 8.04) compared with those with
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Baseline characteristics of EMAS men by vital
status at follow-up
Variable Survived
(n= 2629)
Died
(n= 187)
P*
Mean (SD)
Age (years) 59.2 (10.7) 69.3 (8.3) <0.001
25(OH)D (nmol/l) 64.3 (31.5) 48.3 (28.1) <0.001
1,25(OH)2D3 (pmol/l) 143 (39) 131 (42) <0.001
PTH (pmol/l) 2.97 (1.22) 3.35 (1.90) <0.001
Serum creatinine (μmol/l) 91.1 (16.2) 97.5 (21.8) <0.001
Serum calcium (mmol/l) 2.28 (0.10) 2.31 (0.13) <0.001
Body mass index (kg/m2) 27.6 (4.0) 27.6 (4.9) 0.99
Waist circumference (cm) 98.3 (10.8) 99.5 (12.1) 0.15
PASE score 200 (89) 141 (91) <0.001
PPT rating 24.1 (2.5) 21.3 (3.8) <0.001
Number (%)
Smoking status 0.003
Never smoked 782 (30.4) 35 (19.2)
Former smoker 1273 (49.4) 97 (53.3)
Current smoker 520 (20.2) 50 (27.5)
Frequency of alcohol consumption <0.001
Never 402 (15.4) 53 (29.0)
≤2 days/week 1266 (48.3) 83 (45.3)
≥3 days/week 950 (36.3) 47 (25.7)
Self-reported morbidities <0.001
None 1305 (50.3) 28 (15.5)
One 706 (27.2) 49 (27.1)
Two or more 582 (22.5) 104 (57.4)
Season
Winter 790 (30.1) 57 (30.5) 0.39
Spring 598 (22.7) 33 (17.6)
Summer 304 (11.6) 22 (11.8)
Autumn 937 (35.6) 75 (40.1)
Cardiovascular diseasea 423 (16.1) 76 (40.6) <0.001
High blood pressureb 848 (32.3) 105 (56.2) <0.001
Diabetesc 177 (6.7) 33 (17.7) <0.001
Cancer (ever) 140 (5.3) 28 (15.1) <0.001
Vitamin D/Ca2+ supplementation 14 (0.5) 4 (2) 0.01
*P-value for comparison between ‘survived’ and ‘died’ groups: t-test or
Wilcoxon rank-sum test for continuous variables, χ2-test for categorical
variables.
aSelf-reported heart condition and/or stroke (ever).
bSelf-reported high blood pressure and/or using anti-hypertensives.
cSelf-reported diabetes and/or using anti-diabetic drugs.
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a 25(OH)D level of ≥75 nmol/l. Excluding men who
reported at baseline they had ‘ever been treated for cancer’
attenuated this relationship (25(OH)D <25 nmol/l:
SHR= 2.55; 95% CI = 1.03, 1.99), but the association
remained significant. In contrast, those men in the lowest
quartile of 25(OH)D (<40 nmol/l) had a non-significant
SHR of 2.12 (95% CI = 0.96, 4.71) compared with those in
the highest quartile (>79.1 nmol/l). The cumulative incidence
of cancer mortality estimated from the competing-risks re-
gression for ≥75 nmol/l, 50.0–74.9 nmol/l, 25.0–49.9
nmol/l and <25.0 nmol/l 25(OH)D categories is sum-
marised graphically in the Supplementary data available in
Age and Ageing online, Appendix 2. There were no associa-
tions between cause-specific mortality and 1,25(OH)2D3 or
PTH (all P> 0.1, data not shown).
Discussion
In this prospective, population-based study of middle-aged
and older European men lower levels of both 25(OH)D
and 1,25(OH)2D3 were independently associated with an
increased risk of all-cause mortality. This relationship was
consistent whether vitamin D levels were modelled continu-
ously or classified into quartiles or categories, such that men
who were in the lowest 25% of the range of either 25(OH)D
or 1,25(OH)2D3 had a two-fold higher risk of all-cause mor-
tality after adjustment for potential confounders. In contrast,
the relationship between PTH and all-cause mortality was
broadly non-significant. For cause-specific mortality, we
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Competing-risks regressions: cause-specific
mortality by baseline 25(OH)D
Sub-hazard ratio (95% CI)
CVD death (n= 72) Cancer death (n= 72)
25(OH)D (per SD decrease) No. 1.38 (0.95, 1.99) 1.31 (0.92, 1.86)
25(OH)D quartiles
4: >79.1 nmol/l 619 Reference Reference
3: 58.0–79.1 nmol/l 609 1.29 (0.41, 4.07) 2.04 (0.89, 4.66)
2: 40.0–57.9 nmol/l 611 1.70 (0.59, 4.92) 0.55 (0.19, 1.61)
1: <40.0 nmol/l 613 2.21 (0.75, 6.51) 2.10 (0.94, 4.70)
25(OH)D categories
≥75.0 nmol/l 728 Reference Reference
50.0–74.9 nmol/l 759 1.25 (0.49, 3.20) 1.35 (0.61, 3.03)
25.0–49.9 nmol/l 789 1.77 (0.70, 4.45) 1.05 (0.45, 2.43)
<25.0 nmol/l 176 1.26 (0.40, 3.70) 3.33 (1.38, 8.04)**
Adjusted for age, centre, smoking status, alcohol consumption, self-reported
morbidities, PASE score, PPT rating and serum creatinine. **P < 0.01.
Note: Excluding subjects who reported ‘ever been treated for cancer’ from the
cancer models attenuated the association between 25(OH)D and cancer
mortality, i.e. for the <25.0 nmol/l category, SHR = 2.55 (95% CI = 1.03–6.33,
P < 0.05).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Cox proportional hazard models: all-cause mortality by baseline 25(OH)D, 1,25(OH)2D3 and PTH
Hazard ratio (95% CI)
Unadjusted Model 1 Model 2
25(OH)D (per SD decrease) 1.88 (1.55, 2.26)*** 1.75 (1.42, 2.14)*** 1.45 (1.16, 1.81)**
25(OH)D quartiles
4: >79.1 nmol/l Reference Reference Reference
3: 58.0–79.1 nmol/l 1.93 (1.12, 3.33)* 1.62 (0.93, 2.81) 1.66 (0.91, 3.03)
2: 40.0–57.9 nmol/l 2.41 (1.42, 4.07)** 1.77 (1.03, 3.05)* 1.52 (0.83, 2.77)
1: <40.0 nmol/l 4.33 (2.66, 7.05)*** 3.43 (2.05, 5.73)*** 2.37 (1.33, 4.24)**
25(OH)D categories
≥75.0 nmol/l Reference Reference Reference
50.0–74.9 nmol/l 1.92 (1.17, 3.14)** 1.44 (0.87, 2.38) 1.38 (0.80, 2.38)
25.0–49.9 nmol/l 3.20 (2.03, 5.05)*** 2.55 (1.58, 4.10)*** 1.99 (1.17, 3.36)*
<25.0 nmol/l 6.00 (3.57, 10.1)*** 4.34 (2.51, 7.49)*** 2.28 (1.20, 4.34)*
1,25(OH)2D3 (per SD decrease) 1.40 (1.19, 1.65)*** 1.33 (1.13, 1.58)** 1.24 (1.02, 1.51)*
1,25(OH)2D3 quartiles
4: >164 pmol/l Reference Reference Reference
3: 139–164 pmol/l 1.59 (1.00, 2.52)* 1.53 (0.96, 2.43) 1.66 (0.99, 2.78)
2: 114–138 pmol/l 1.24 (0.76, 2.03) 1.13 (0.69, 1.85) 0.94 (0.52, 1.68)
1: <114 pmol/l 2.28 (1.48, 3.52)*** 2.05 (1.32, 3.20)** 1.77 (1.05, 2.96)*
PTH (per SD increase) 1.28 (1.14, 1.43)*** 1.15 (1.01, 1.30)* 1.04 (0.90, 1.20)
PTH quartiles
1: <2.15 pmol/l Reference Reference Reference
2: 2.15–2.76 pmol/l 0.89 (0.58, 1.36) 0.79 (0.51, 1.20) 0.84 (0.52, 1.37)
3: 2.77–3.60 pmol/l 0.65 (0.41, 1.03) 0.54 (0.34, 0.86)* 0.56 (0.33, 0.95)*
4: >3.60 pmol/l 1.53 (1.05, 2.23)* 1.10 (0.74, 1.62) 1.02 (0.65, 1.60)
Model 1: adjusted for age and centre. Model 2: adjusted for age, centre, smoking status, alcohol consumption, self-reported morbidities, PASE score, PPT rating and
serum creatinine. *P< 0.05, **P< 0.01 and ***P< 0.001.
Note: Including PTH in Model 2 (25(OH)D or 1,25(OH)2D3), or forcing BMI, waist circumference, serum calcium or season into Model 2 (25(OH)D, 1,25(OH)2D3
or PTH) did not markedly alter the magnitude or significance of the associations (data not shown). Using the IOM cut points for 25(OH)D [28], the HRs for Model 2
were: >50 nmol/l (reference category), 30–50 nmol/l (HR = 1.53; 95% CI = 1.03, 2.27) and <30 nmol/l (HR = 1.98; 95% CI = 1.25, 3.12).
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observed a significant association between 25(OH)D and
cancer mortality among men with a 25(OH)D level of <25
nmol/l only, i.e. more than a three-fold increased risk of
cancer-related death compared with those with a 25(OH)D
level of ≥75 nmol/l.
To our knowledge, this is the first study to simultaneously
examine the associations of all of the key metabolites of the
vitamin D endocrine system with all-cause and cause-
specific mortality in a sample of community-dwelling indivi-
duals. Two recent meta-analyses of cohort studies examining
vitamin D deficiency and mortality risk in the general popu-
lation reported a non-linear decrease in mortality risk with
increasing serum 25(OH)D levels, with an optimal concen-
tration between 75 and 87.5 nmol/l [13], and an 8% lower
mortality in the general elderly population associated with a
20 nmol/l increase in 25(OH)D levels [12]. Our findings of
a significantly increased risk of all-cause mortality at 25(OH)
D concentrations considered ‘insufficient’ (<50 nmol/l) are
in broad agreement with these meta-analyses [12, 13], and
with Schottker et al. [29] who recently reported a significantly
increased overall mortality among participants of the
population-based ESTHER study (aged 50–74 years) who
had a 25(OH)D level of <50 nmol/l.
There are fewer data describing the association of 1,25
(OH)2D3 and PTH with all-cause mortality, and to the best
of our knowledge ours is the first study to examine the rela-
tionship between 1,25(OH)2D and mortality in a commu-
nity-based setting. Dobnig et al. [17] observed a significant
association of both low 1,25(OH)2D and 25(OH)D levels
with all-cause and cardiovascular mortality among male and
female coronary angioplasty patients (mean age 62 years).
Kendrick et al. [30] reported an increased risk of mortality
and progression to maintenance dialysis in mainly male
patients with advanced kidney disease who were in the lowest
tertile of 1,25(OH)2D. How generalisable these findings
from patient populations with pre-existing disease are to
community-dwelling individuals is uncertain. Given that
serum 1,25(OH)2D3 concentrations are typically 1,000-fold
lower than 25(OH)D [3], we used a sensitive LC–MS/MS
method for measuring 1,25(OH)2D3 [23] and our data
support a modest association between lower levels of 1,25
(OH)2D3 and increased all-cause mortality.
A number of recent population-based cohort studies
have examined the prospective association between 25(OH)
D or PTH and cause-specific mortality. Using data from
NHANES III, Freedman and colleagues observed an
inverse relationship between 25(OH)D and colorectal cancer
mortality during 146,578 person-years of follow-up [31]. In
addition to all-cause mortality, Schottker et al. found strong
associations between vitamin D deficiency (25(OH)D <30
nmol/l) and mortality from cardiovascular, cancer and
respiratory causes among participants of the ESTHER study
[29]. The Uppsala Longitudinal Study of Adult Men
(ULSAM) found that higher PTH levels were associated
with greater cardiovascular mortality in community-dwelling
men (mean age 71 years), even among those without any
sign of disturbed mineral metabolism [19]. However, we did
not observe significant associations between cardiovascular
mortality and 25(OH)D, 1,25(OH)2D3 or PTH. It is pos-
sible that we failed to find any relationship with cardiovascu-
lar mortality due to a lack of power (number of
cardiovascular deaths = 72) and/or misclassification in cause
of death. The ESTHER study, in contrast, reported 350
deaths due to cardiovascular disease [29], while the ULSAM
study reported 117 cardiovascular deaths defined using the
Swedish Cause of Death Register [19]. Cause of death in
EMAS was not validated by independent sources in 10%
of cases, necessitating some caution in our analysis of cause-
specific mortality. Nonetheless, we did observe a significant
association between cancer mortality and 25(OH)D levels
<25 nmol/l, where the number of cancer deaths equalled
those due to cardiovascular disease. Our observation of a
three-fold increase in risk of cancer mortality only in men
with 25(OH)D <25 nmol/l suggests that a threshold may
exist, with an association only emerging when 25(OH)D is
in the ‘deficient’ range.
Our previous cross-sectional data have shown that low 25
(OH)D is associated with various adverse health states, in-
cluding frailty [32], depression [6], decreased cognitive func-
tion [33] and metabolic syndrome [34]. While the nature of
any biological mechanisms linking the vitamin D endocrine
axis with adverse outcomes remain undefined, research inter-
est in the non-skeletal effects of vitamin D has, in part, been
motivated by the observation that the vitamin D receptor,
and the enzyme responsible for converting 25(OH)D to 1,25
(OH)2D (1α-hydroxylase), co-localise in a wide variety of cell
types and tissues [35]. Along with in vitro data, this supports
the notion that 1,25(OH)2D may exert paracrine effects
influencing gene expression in vivo [36]. However, there is no
direct evidence that 25(OH)D or 1,25(OH)2D is causally
involved in non-skeletal pathophysiological mechanisms
associated with mortality, and our findings do not differenti-
ate whether low 25(OH)D/1,25(OH)2D3 is the cause or me-
diator of higher mortality or merely a non-specific marker of,
or adaptive response to, poor health. Nonetheless, a key
message here is that vitamin D deficiency should be recog-
nised as not only having implications for skeletal health but
may also offer a window of opportunity for improving ageing
men’s general health, and subsequent assessment and reduc-
tion of adverse outcomes.
The main strengths of our study are that it was prospect-
ive and population based, with detailed phenotyping of men
using standardised assessments. Limitations of the EMAS
study have been described in detail previously [20], as have
problems pertaining to the use of single measurements of
vitamin D and PTH [33]. Our overall loss to follow-up was
13% and compared with participants, those lost to follow-up
had lower mean 25(OH)D (64.3 versus 55.6 nmol/l) and
higher PTH (3.0 versus 3.2 pmol/l) levels, poorer PPT
rating (mean 24.1 versus 23.5), a higher prevalence of two or
more co-morbidities (22.5 versus 30.9%) and were more
likely to smoke (20.2 versus 26.2%), and as a consequence
may have had an increased mortality risk. Our data may,
therefore, underestimate the true mortality of the baseline
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cohort, although this should not affect the findings here
which were based on an internal comparison of participants.
Loss to follow-up also varied between centres (4.4–14.5%),
although adjusting for centre in the analyses did not alter the
main findings. Finally, we cannot discount that some associa-
tions may be due to unmeasured factors and/or residual
confounding.
In summary, we found that low levels of 25(OH)D or 1,25
(OH)2D3 are associated with an increased risk of all-cause
mortality, largely independent of confounding health and life-
style factors. We also observed a significantly increased risk of
cancer mortality among men with a baseline serum 25(OH)D
level of <25 nmol/l. While our data suggest that maintaining
serum 25(OH)D levels >50 nmol/l may be beneficial to
general health, any aetiological link between the vitamin D
endocrine axis and mortality remains undefined.
Key points
• Serum levels of 25-hydroxyvitamin D and
1,25-dihydroxyvitamin D are negatively associated with
all-cause mortality risk.
• Very low levels of 25-hydroxyvitamin D were associated
with an increased risk of cancer mortality.
• Whether the link between the vitamin D endocrine axis
and mortality has any causal basis remains unknown.
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Abstract
Background: numbers of elderly people are increasing worldwide. This increases the importance of the specialty of geriatric
medicine. Recruitment to the specialty may not be keeping pace with need.
Objectives: to report trends in junior doctors’ career choices for geriatric medicine, factors that influence career choice, and
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